Pharmacological modulation of the tissue response to implanted polylactic-co-glycolic acid microspheres

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 44, Issue 1, 1997, Pages 89-102

  Daugherty, Ann L ^a   Cleland, Jeffrey L ^a   Duenas, Eileen M ^a   Mrsny, Randall J ^a  

^a GENENTECH INC   (United States)

Author keywords

Biocompatibility; Inflammation; Microspheres; Polylactic acid; Polylactic co glycolic acid; Protein delivery; Sustained release; Tissue response; Wound healing

Indexed keywords

CYCLOSPORIN A; DEXAMETHASONE; HEPARIN; LEVAMISOLE; MICROSPHERE; POLYGLACTIN; RECOMBINANT FIBROBLAST GROWTH FACTOR; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; DRUG FORMULATION; DRUG IMPLANT; DRUG IMPLANTATION; FOREIGN BODY REACTION; HISTOPATHOLOGY; MALE; NONHUMAN; RAT; WOUND HEALING;

EID: 0031402135     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(97)00065-9     Document Type: Article

References (47)

1. P.M. Henson, and R.B. Johnston Jr, Tissue injury in inflammation. J. Clin. Invest., 79 (1987) 669-674.
2. B. Goldberg, and M. Rabinovitch, Connective tissue, in: Weiss, L. (Eds.), Cell and Tissue Biology, 6th Ed. Urban and Schwarzberg, Baltimore, MD, 1983, pp. 156-188.
3. J.M. Davidson, Wound repair, in: J.I. Gallin, I.M. Goldstein and R. Snyderman (Eds.), Inflammation: Basic Principles and Clinical Correlates. Raven Press, New York, 1992, pp. 809-819.
4. J.M. Anderson, In vivo biocompatibility of implantable delivery systems and biomaterials. Eur. J. Pharmacol. Biopharmacol., 40 (1994) 1-8.
5. J.M. Anderson, Mechanisms of inflammation and infection with implanted devices. Cardiovasc. Pathol., 2 (1993) 33s-41s.
6. J.M. Andersen, Perspectives on in vivo testing of biomaterials, prostheses and artificial organs. J. Am. Coll. Toxicol., 7 (1988) 469-479.
7. J.M. Anderson, Perspectives on the in vivo responses of biodegradable polymers. In: J.O. Hollinger, (Eds.), Biomedical Applications of Synthetic Biodegradable Polymers, CRC Press, Boca Raton, 1995, pp. 223-231.
8. Z.R. Glaser, Some unanticipated changes in implant biocompatibility produced by alteration of the surface of the implant. Pharmacopeial Forum, 19 (1993) 5035-5039.
9. J.M. Anderson, Inflammation and the foreign body response. Prob. Gen. Surg., 11 (1994) 147-160.
10. N.P. Ziats, K.M. Miller and J.M. Anderson, In vitro and in vivo interactions of cells with biomaterials. Biomaterials, 9 (1988) 5-13.
11. G. Visscher, R. Robison, H. Mauldin, J. Fong, J. Pearson and G. Argentieri, Biodegradation of and tissue reaction to 50:50 poly (DL-lactide-co-glycolide) microcapsules. J. Biomed. Mater. Res., 19 (1985) 349-365.
12. J.L. Cleland, Protein delivery from biodegradable microspheres. in: L. Saunders and W. Hendren (Eds.), Protein Delivery: Physical Systems, Plenum Press, New York, (1997), pp. 1-43.
13. O.L. Johnson, J.L. Cleland, H.J. Lee, M. Charni's, E.T. Duenas, W. Jaworowicz, D. Shepard, A. Shahzamani, A.J.S. Jones and S.D. Putney, A month-long effect from a single injection of microencapsulated human growth hormone. Nature Med., 2 (1996) 795-799.
14. R.A. Miller, J.M. Brady and D.E. Cutright, Degradation rates of oral resorbable implants (polylactates and polyglycolates): Rate modification with changes in PLA/PGA co-polymer ratios. J. Biomed. Mater. Res., 11 (1977) 711-719.
15. D.T. O'Hagan, H. Jeffery, M.J.J. Roberts, J.P. McGee and S.S. Davis, Controlled release microparticles for vaccine development. Vaccine, 9 (1991) 768-771.
16. J.H. Eldridge, J.K. Stass, J.A. Meulbroek, J.R. McGhee, T.R. Tice and R.M. Gilley, Biodegradable microspheres as a vaccine delivery system. Mol. Immunol., 28 (1991) 287-294.
17. B.J. Sugarman, G.D. Lewis, T.E. Eessalu, B.B. Aggerwal and H.M. Shepard, Effects of growth factors on the antiproliferative activity of tumor necrosis factors. Cancer Res., 47 (1987) 780-786.
18. E. Canova-Davis, I.P. Baldonado and G.M. Teshima, Characterization of chemically synthesized human relaxin by high performance liquid chromatography. J. Chromatogr., 508 (1990) 81-96.
19. J.L. Cleland, Design and production of single immunization vaccines using polylactide polyglycolide microsphere systems. in: M.F. Powell and M. Newman (Eds.), Vaccine Design: The Subunit Approach, Plenum, New York, 1995, pp. 439-472.
20. S.S Shah, Y. Cha and C.G. Pitt, Poly(glycolic acid-co-DL-lactic acid): Diffusion or degradation controlled drug delivery? J. Contr. Rel., 18 (1992) 261-270.
21. J.L. Cleland, E.T. Duenas, J. Yang, H. Chu, V. Mukku, A. Mac, M. Roussakis, D. Yeung, D. Brooks, Y.F. Maa, C. Hsu and A.J.S. Jones, One month continuous release recombinant human growth hormone-PLGA formulations. Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 22 (1995) 149-150.
22. J.L. Cleland, E.T. Duenas, A. Daugherty, M. Marian, J. Yang, M. Wilson, A. Shahzamani, H. Chu, V. Mukku, Y.F. Maa, C. Hsu and A.J.S. Jones, Characterization of recombinant human growth hormone-PLGA formulations in animals. Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 22 (1995) 143-144.
23. R.L. Duerr, M.D. McKirnan, R.D. Gim, R.G. Clark, K.R. Chien and J. Ross, Cardiovascular effects of insulin-like growth factor-1 and growth hormone in chronic left ventricular failure in the rat. Circulation, 93 (1996) 2188-2196.
24. P.J. Fielder, D.L. Mortensen, P. Mallet, B. Carlsson, R.C. Baxter and R.G. Clark, Differential long-term effects of insulin-like growth factor-I (IGF-I), growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats. Endocrinology, 137 (1996) 1913-1920.
25. R. Marchant, A. Hiltner, C. Hamlin, A. Rabinovitch, R. Slobodkin and J.M. Anderson, In vivo biocompatibility studies. I. The cage implant system and a biodegradable hydrogel. J. Biomed. Mater. Res., 17 (1983) 301-325.
26. J.D. Dugan, A.B. Roberts, M.B. Sporn, and B.M. Glaser, Transforming growth factor β(TGF-β) inhibits neovascularization in vivo. J. Cell Biol., 107 (1988) 579a.
27. A.B. Roberts, M.B. Sporn, R.K. Assoian, J.M. Smith, N.S. Roche, L.M. Wakefield, U.I. Heine, L.A. Liotta, V. Falanga, J.H. Kehrl and A.S. Fauci, Transforming growth factor type-β: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl. Acad. Sci. USA, 83 (1986) 4167 - 4171.
28. T.A. Mustoe, G.F. Pierce, A. Thomason, P. Gramates, M.B. Sporn and T.F. Deuel, Accelerated healing of incisional wounds in rats induced by transforming growth factor-β. Science, 237 (1987) 1333-1336.
29. B. Sherry and A. Cerami, Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses. J. Cell Biol., 107 (1988) 1269-1277.
30. H.M. Gordon, G. Kucera, R. Salvo and J.M. Boss, Tumor necrosis factor induces genes involved in inflammation, cellular and tissue repair and metabolism in murine fibroblasts. J. Immunol., 148 (1992) 4021-4027.
31. M. Centrella, T.L. McCarthy and E. Canalis, Tumor necrosis factor-α inhibits collagen synthesis and alkaline phosphatase activity independently of its effect on deoxyribonucleic acid synthesis in osteoblast-enriched bone cell cultures. Endocrinology, 123 (1988) 1442-1448.
32. J.W. Hadden, C. Lopez, R.J. O'Reilly and E.M. Hadden, Levamisole and inosiplex: Antiviral agents with immunopotentiating action. Ann. New York Acad. Sci., 284 (1977) 139-152.
33. R.Y. Calne, Pharmacological immunosuppression in clinical organ grafting. Observations on four agents: Cyclosporin A, Asta 5122 (cytimum), λ carrageenan, and promethazine hydrochloride. Clin. Exp. Immunol., 35 (1979) 1-9.
34. A.E. Postlethwaite, J. Keski-Oja, H. Moses and A. Kang, Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor-β. J. Exp. Med., 165 (1987) 251-256.
35. G.F. Pierce, D. Brown and T.A. Mustoe, Quantitative analysis of inflammatory cell influx, procollagen type I synthesis, and collagen cross-linking in incisional wounds: Influence of PDGFBB and TGF-β1 therapy. J. Lab. Clin. Med., 117 (1991) 373-382.
36. G.D. Bryant-Greenwood, The human relaxins: Consensus and dissent. Mol. Cell. Endocrinol., 79 (1991) C125-132.
37. E.N. Unemori and E.P. Amento, Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J. Biol. Chem., 265 (1990) 10681-10685.
38. E.N. Unemori, L.S. Beck, W.P.L. Lee, Y. Xu, M. Siegel, G. Keller, H.D. Liggitt, E.A. Bauer and E.P. Amento, Human relaxin decreases collagen accumulation in vivo in two rodent models of fibrosis. J. Invest. Dermatol., 101 (1993) 280-285.
39. W. Pawlina, L.H. Larkin, S. Ogilvie and S.D. Frost, Human relaxin inhibits division but not differentiation of 3T3-L1 cells. Mol. Cell. Endocrinol., 72 (1990) 55-61.
40. J.C. Chambard and J. Pouyssgur, TGF-β inhibits growth factor-induced DNA synthesis in hamster fibroblasts without affecting the early mitogenic events. J. Cell Biol., 135 (1987) 101-107.
41. E.J. Kovacs, Fibrogenic cytokines: The role of immune mediators in the development of scar tissue. Immunol. Today, 12 (1991) 17-23.
42. M.M. Shull, I. Ormsby, A.B. Kier, S. Pawlowski, R.J. Diebold, M. Yin, R. Allen, C. Sidman, G. Proetzel, D. Calvin, N. Annunziata and T. Doetschman, Targeted disrupted of the mouse transforming growth factor-β1 gene results in multifocal inflammation disease. Nature, 359 (1992) 693-699.
43. Y. Myoken, M. Kan, G.H. Sato, W.L. McKeehan and J.D. Sato, Bifunctional effects of transforming growth factor-β (TGF-β) on endothelial cell growth correlates with phenotypes of TGF-β binding sites. Exp. Cell Res., 191 (1990) 299-304.
44. Z. Yan, S. Winawer and E. Friedman, Two different signal transduction pathways can be activated by transforming growth factor β1 in epithelial cells. J. Biol. Chem., 269 (1994) 13231-13237.
45. R.M. Niles, N.L. Thompson and F. Fenton, Expression of TGF-β during in vitro differentiation of hamster tracheal epithelial cells. In vitro Cell. Devel. Biol., 30A (1994) 256-262.
46. R.K. Assoian, B.E. Fleurdelys, H.C. Stevenson, P.J. Miller and D.K. Madtes, Expression and secretion of type β transforming growth factor by activated human macrophages. Proc. Natl. Acad. Sci. USA, 84 (1987) 6020-6024.
47. J.L. Gabrilove, G. Wong, E. Bollenbacher, K. White, S. Kojima and E.L. Wilson, Basic fibroblast growth factor counteracts the suppressive effect of transforming growth factor-β1 on human myeloid progenitor cells. Blood, 81 (1993) 909-915.